olvimulogene nanivacirepvec + carboplatin + cisplatin

This combination therapy regimen consists of olvimulogene nanivacirepvec (Olvi-Vec), an engineered oncolytic vaccinia virus, administered in sequence with platinum-doublet chemotherapy (specifically carboplatin or cisplatin) and an immune checkpoint inhibitor. Developed by Genelux Corporation, Olvi-Vec is designed to selectively infect and lyse cancer cells, induce a systemic anti-tumor immune response, and remodel the tumor microenvironment to overcome resistance to standard therapies. The regimen is currently being evaluated in Phase 2 clinical trials (such as the VIRO-25 study) for the treatment of patients with advanced or metastatic non-small cell lung cancer (NSCLC) who have experienced disease progression following first-line immune checkpoint inhibitor-based therapy. The goal of the combination is to resensitize tumors to platinum-based chemotherapy and enhance the overall efficacy of the treatment regimen.

Other names

Olvimulogene nanivacirepvecOlvi-Vec + platinum-doublet chemotherapy